Pharmacological manipulation of cell death: Clinical applications in sight?

Journal of Clinical Investigation

Volumn 115, Issue 10, 2005, Pages 2610-2617

  Green, Douglas R ^a   Kroemer, Guido ^b,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; ADALIMUMAB; ADVEXIN; AEG 35156; AGO 14699; AMIFOSTINE; ANTIOXIDANT; APOPTOSIS INHIBITOR; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BORTEZOMIB; CARRIER PROTEIN; CASPASE INHIBITOR; CEP 1347; CETUXIMAB; CISPLATIN; DEATH RECEPTOR; ERLOTINIB; ETANERCEPT; GEFITINIB; GOSSYPOL; IDEBENONE; IDN 6734; IMATINIB; INFLIXIMAB; INO 1001; ISIS 104828; LY 2181308; MINOCYCLINE; MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INHIBITOR; NICOTINAMIDE; NORPHENAZONE; OBLIMERSEN; ONYX 015; PRALNACASAN; PRO 1764; PROTEIN INHIBITOR; PROTEINASE; RASAGILINE; SCH 58500; SORAFENIB; TEMSIROLIMUS; TRANSCRIPTION FACTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE HEART INFARCTION; ALCOHOL LIVER DISEASE; ANKYLOSING SPONDYLITIS; APOPTOSIS; ATAXIA TELANGIECTASIA; CELL DEATH; CELL KILLING; CELL PERMEABILIZATION; CLINICAL TRIAL; CROHN DISEASE; DRUG INDICATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; FRIEDREICH ATAXIA; HEPATITIS C; HUMAN; HUNTINGTON CHOREA; ISCHEMIA; LUNG NON SMALL CELL CANCER; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; NEPHROTOXICITY; NONHUMAN; OVARY CARCINOMA; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; PSORIASIS; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CASPASES; CELL MEMBRANE PERMEABILITY; CLINICAL TRIALS; DRUG DESIGN; DRUG THERAPY; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; MITOCHONDRIA; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 26444434342     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI26321     Document Type: Review

References (78)

1. Wyllie, A.M., Kerr, J.F., and Currie, A.R. 1980. Cell death: the significance of apoptosis. Int. Rev. Cytol. 68:251-306.
2. Fuentes-Prior, P., and Salvesen, G.S. 2004. The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem. J. 384:201-232.
3. Debatin, K.M., and Krammer, P.H. 2004. Death receptors in chemotherapy and cancer. Oncogene. 23:2950-2966.
4. Green, D.R., and Kroemer, G. 2004. The pathophysiology of mitochondrial cell death. Science. 305:626-629.
5. Bao, Q., Riedl, S.J., and Shi, Y. 2005. Structure of Apaf-1 in the auto-inhibited form: a critical role for ADP. Cell Cycle. 4:1001-1003.
6. Acehan, D., et al. 2002. Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol. Cell. 9:423-432.
7. Chipuk J.E., and Green, D.R. 2005. Do inducers of apoptosis trigger caspase-independent cell death? Nat. Rev. Mol. Cell Biol. 6:268-275.
8. Kroemer, G., and Martin, S.J. 2005. Caspase-independent cell death. Nat. Med. 11:725-730.
9. Susin, S.A., et al. 1999. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 397:441-446.
10. Li, L.Y., Luo, X., and Wang, X. 2001. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature. 412:95-99.
11. Kokoszka, J.E., et al. 2004. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature. 427:461-465.
12. Nakagawa, T., et al. 2005. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature. 434:652-658.
13. Baines, C.P., et al. 2005. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature. 434:658-662.
14. Basso, E., et al. 2005. Properties of the permeability transition pore in mitochondria devoid of Cyclophilin D. J. Biol. Chem. 280:18558-18561.
15. Kuwana, T., et al. 2002. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell. 111:331-342.
16. Kuwana, T., et al. 2005. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol. Cell. 17:525-535.
17. Wei, M.C., et al. 2001. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 292:727-730.
18. Letai, A., et al. 2002. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2:183-192.
19. Chen, L., et al. 2005. Differential targeting of pro-survival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell. 17:393-403.
20. Oltersdorf, T., et al. 2005. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 435:677-681.
21. Zhang, J., Liu, X., Scherer, D.C., van Kaer, L., Wang, X., and Xu, M. 1998. Resistance to DNA fragmentation and chromatin condensation in mice lacking the DNA fragmentation factor 45. Proc. Natl. Acad. Sci. U. S. A. 95:12480-12485.
22. Susin, S.A., et al. 2000. Two distinct pathways leading to nuclear apoptosis. J. Exp. Med. 192:571-579.
23. Yu, L., et al. 2004. Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science. 304:1500-1502.
24. Hirsch, T., et al. 1997. The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death. Oncogens. 15:1573-1582.
25. Xu, P., Rogers, S.J., and Roossinck, M.J. 2004. Expression of antiapoptotic genes bcl-xL and ced-9 in tomato enhances tolerance to viral-induced necrosis and abiotic stress. Proc. Natl. Acad. Sci. U. S. A. 101:15805-15810.
26. Shimizu, S., et al. 2004. A role of Bcl-2 family of proteins in non-apoptotic programmed cell death dependent on autophagy genes. Nat. Cell Biol. 6:1221-1228.
27. Schotte, P., Declercq, W., Van Huffel, S., Vandenabeele, P., and Beyaert, R. 1999. Non-specific effects of methyl ketone peptide inhibitors of caspases. FEBS Lett. 442:117-121.
28. Knoblach, S.M., et al. 2004. Caspase inhibitor z-DEVD-fmk attenuates calpain and necrotic cell death in vitro and after traumatic brain injury. J. Cereb. Blood Flow Metab. 24:1119-1132.
29. Tomioka, M., et al. 2002. In vivo role of caspases in excitotoxic neuronal death: generation and analysis of transgenic mice expressing baculoviral caspase inhibitor, p35, in postnatal neurons. Brain Res. Mol. Brain Res. 108:18-32.
30. Ferri, K.F., and Kroemer, G.K. 2001. Organelle-specific initiation of cell death pathways. Nat. Cell Biol. 3:E255-E263.
31. Marchenko, N.D., Zaika, A., and Moll, U.M. 2000. Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J. Biol. Chem. 275:16202-16212.
32. Chipuk, J.E., et al. 2004. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 303:1010-1014.
33. Leu, J.I., Dumont, P., Hafey, M., Murphy, M.E., and George, D.L. 2004. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell Biol. 6:443-450.
34. Boya, P., et al. 2003. Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J. Exp. Med. 197:1323-1334.
35. Erdal, H., et al. 2005. Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. Proc. Natl. Acad. Sci. U. S. A. 102:192-197.
36. Boya, P., et al. 2003. Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J. Exp. Med. 197:1323-1334.
37. Green, D.R., and Evan, G.I. 2002. A matter of life and death. Cancer Cell. 1:19-30.
38. le Coutre, P., et al. 1999. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl. Cancer Inst. 91:163-168.
39. Okada, M. et al. 2004. A novel mechanism for imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity. Blood. 103:2299-2307.
40. Amaravadi, R., and Thompson, C.B. 2005. The survival kinases Akt and Pim as potential pharmacological targets. J. Clin. Invest. 115:2618-2624. doi:10.1172/JCI26273.
41. Luo, J.-L., Kamata, H., and Karin, M. 2005. IKK/NF-κB signaling: balancing life and death - a new approach to cancer therapy. J. Clin. Invest. 115:2625-2632. doi:10.1172/JCI26322.
42. Beere, H.M. 2005. Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J. Clin. Invest. 115:2633-2639. doi:10.1172/JCI26471.
43. Bouchier-Hayes, L., Lartigue, L., and Newmeyer, D.D. 2005. Mitochondria: pharmacological manipulation of cell death. J. Clin. Invest. 115:2640-2647. doi:10.1172/JCI26274.
44. Letai, A. 2005. Pharmacological manipulation of Bcl-2 family members to control cell death. J. Clin. Invest. 115:2648-2655. doi:10.1172/JCI26250.
45. Xu, C., Bailly-Maitre, B., and Reed, J.C. 2005. Endoplasmic reticulum stress: cell life and death decisions. J. Clin. Invest. 115:2656-2664. doi:10.1172/JCI26373.
46. Lavrik, I.N., Golks, A., and Krammer, P.H. 2005. Caspases: pharmacological manipulation of cell death. J. Clin. Invest. 115:2665-2672. doi:10.1172/JCI26252.
47. Wright, C.W., and Duckett, C.S. 2005. Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J. Clin. Invest. 115:2673-2678. doi:10.1172/JCI26251.
48. Levine, B., and Yuan, J. 2005. Autophagy in cell death: an innocent convict? J. Clin. Invest. 115:2679-2688. doi:10.1172/JCI26390.
49. Cao, G., et al. 2002. In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J. Neurosci. 22:5423-5431.
50. Sugioka, R., et al. 2003. BH4-domain peptide from Bcl-xL exerts anti-apoptotic activity in vivo. Oncogene. 22:8432-8440.
51. Akhtar, R.S., Ness, J.M., and Roth, K.A. 2004. Bcl-2 family regulation of neuronal development and neurodegeneration. Biochim. Biophys. Acta. 1644:189-203.
52. Tanaka, M., et al. 2004. Cardiomyocyte-specific Bcl-2 overexpression attenuates ischemia-reperfusion injury, immune response during acute rejection, and graft coronary artery disease. Blood. 104:3789-3796.
53. Weisleder, N., Taffet, G.E., and Capetanaki, Y. 2004. Bcl-2 overexpression corrects mitochondrial defects and ameliorates inherited desmin null cardiomyopathy. Proc. Natl. Acad. Sci. U. S. A. 101:769-774.
54. Yang, L., et al. 2004. A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo. Neurobiol. Dis. 17:250-259.
55. Methot, N., et al. 2004. Differential efficacy of caspase inhibitors on apoptosis markers during sepsis in rats and implication for fractional inhibition requirements for therapeutics. J. Exp. Med. 199:199-207.
56. Wang, J., et al. 2004. Caspase inhibitors, but not c-Jun NH2-terminal kinase inhibitor treatment, prevent cisplatin-induced hearing loss. Cancer Res. 64:9217-9224.
57. Matsui, J.I., et al. 2003. Caspase inhibitors promote vestibular hair cell survival and function after aminoglycoside treatment in vivo. J. Neurosci. 23:6111-6122.
58. Liu, X., Van Vleet, T., and Schnellmann, R.G. 2004. The role of calpain in oncotic cell death. Annu. Rev. Pharmacol. Toxicol. 44:349-370.
59. Crocker, S.J., et al. 2003. Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J. Neurosci. 23:4081-4091.
60. Takano, J., et al. 2005. Calpain mediates excitotoxic DNA fragmentation via mitochondrial pathways in adult brains: evidence from calpastatin-mutant mice. J. Biol. Chem. 280:16175-16184.
61. Spencer, M.J., and Mellgren, R.L. 2002. Overexpression of a calpastatin transgene in mdx muscle reduces dystrophic pathology. Hum. Mol. Genet. 11:2645-2655.
62. Guicciardi, M.A., Leist, M., and Gores, G.J. 2004. Lysosomes in cell death. Oncogene. 23:2881-2890.
63. Cilenti, L., et al. 2005. Omi/HtrA2 protease mediates cisplatin-induced cell death in renal cells. Am. J. Physiol. Renal Physiol. 288:F371-F379.
64. Liu, H.R., et al. 2005. Role of Omi/HtrA2 in apoptotic cell death after myocardial ischemia and reperfusion. Circulation. 111:90-96.
65. Cregan, S.P., et al. 2002. Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J. Cell Biol. 158:507-517.
66. Demjen, D., et al. 2004. Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. Nat. Med. 10:389-395.
67. Martin-Villalba, A., et al. 2001. Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ. 8:679-686.
68. Graham, E.M., et al. 2004. Neonatal mice lacking functional Fas death receptors are resistant to hypoxic-ischemic brain injury. Neurobiol. Dis. 17:89-98.
69. Yoshino, O., et al. 2004. The role of Fas-mediated apoptosis after traumatic spinal cord injury. Spine. 29:1394-1404.
70. Eichhorst, S.T., et al. 2004. Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic liver damage in mice. Nat. Med. 10:602-609.
71. Komarov, P.G., et al. 1999. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 285:1733-1737.
72. Hong, S.J., Dawson, T.M., and Dawson, V.L. 2004. Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol. Sci. 25:259-264.
73. Xiao, C.V., et al. 2005. Poly(ADP-ribose) polymerase promotes cardiac remodeling, contractile failure and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure. J. Pharmacol. Exp. Ther. 312:891-898.
74. Zheng, J., Devalaraja-Narashimha, K., Singaravelu, K., and Padanilam, B.J. 2005. Poly(ADP-ribose) polymerase-1 gene ablation protects mice from ischemic renal injury. Am. J. Physiol. Renal Physiol. 288:F387-F398.
75. Hirt, L., et al. 2004. D-JNKI1, a cell-penetrating c-Jun-N-terminal kinase inhibitor, protects against cell death in severe cerebral ischemia. Stroke. 35:1738-1743.
76. Kuan, C.V., et al. 2003. A critical role of neural-specific JNK3 for ischemic apoptosis. Proc. Natl. Acad. Sci. U. S. A. 100:15184-15189.
77. Wang, L.H., Besirli, C.G., and Johnson, E.M., Jr. 2004. Mixed-lineage kinases: a target for the prevention of neurodegeneration. Annu. Rev. Pharmacol. Toxicol. 44:451-474.
78. Grunhagen, D.J., et al. 2004. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple intransit metastases. Ann. Surg. 240:939-947.